Patents Examined by Bridget E. Bunner
  • Patent number: 11655294
    Abstract: Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: May 23, 2023
    Inventors: Francisco Leon, Wayne H. Tsuji
  • Patent number: 11654104
    Abstract: The present application provides methods of administering an IL-22 dimer to an individual, such as a human individual, comprising intravenously administering to the individual an effective amount of an IL-22 dimer, wherein the amount of the IL-22 dimer is about 2 ?g/kg to about 200 ?g/kg (such as about 10 ?g/kg to about 45 ?g/kg), as well as methods of treating diseases by following such administration methods. Also provided are kits, unit dosages, and articles of manufacture for use in any one of the methods described herein.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: May 23, 2023
    Assignee: Evive Biotechnology (Shanghai) Ltd
    Inventors: Xiaoqiang Yan, Cheng Huang, Dongdong Wu, Kaiyang Tang, Yuliang Huang
  • Patent number: 11655299
    Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: May 23, 2023
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Denise Mazess Herpai
  • Patent number: 11649436
    Abstract: The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: May 16, 2023
    Inventors: Tai Gyu Kim, Hyun Jung Sohn, Su Eon Kim
  • Patent number: 11634688
    Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluriptent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: April 25, 2023
    Assignee: Fate Therapeutics, Inc.
    Inventors: Bahram Valamehr, Raedun Clarke
  • Patent number: 11634687
    Abstract: The present invention relates generally to the identification and isolation of human otic progenitor cells. More specifically, the present invention relates to a method of using cell markers to identify and isolate human otic progenitor cells from a mixed population of cells, methods of enrichment and production of human otic progenitor cells, and associated kits for use in identification and/or isolation of human otic progenitor cells, wherein the cell markers are selected from SSEA1 (CD15), disialoganglioside GD3, TRA-2-49 (liver/bone/kidney alkaline phosphatase), SSEA4, ganglioside GD2 and CD141.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 25, 2023
    Inventors: Carlos Marcelo Nicolas Rivolta, Sarah Louise Boddy
  • Patent number: 11629195
    Abstract: The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human IL2 receptor gamma (IL2R?). Methods for treating or preventing diseases mediated by IL2R? (e.g., graft vs host disease) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: April 18, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jamie M. Orengo, Andrew J. Murphy
  • Patent number: 11628201
    Abstract: The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: April 18, 2023
    Assignee: Cleveland BioLabs, Inc.
    Inventors: Anatoli Gleiberman, Lyudmila Burdelya, Andrei Gudkov
  • Patent number: 11604194
    Abstract: The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: March 14, 2023
    Inventors: Noriaki Arakawa, Hisashi Hirano, Hiroji Uemura, Yusuke Ito, Shohei Myoba, Norihisa Ohtake
  • Patent number: 11602598
    Abstract: A prefilled syringe and a method of filling a syringe with a pegfilgrastim solution to provide a target extracted volume of pegfilgrastim solution from the syringe are described. A method includes selecting the target extracted volume of pegfilgrastim solution, determining an estimated drug transfer loss, determining an estimated syringe dead volume, filling the syringe with a volume of pegfilgrastim solution comprising at least the target extracted volume plus the estimated drug transfer loss plus the estimated syringe dead volume.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: March 14, 2023
    Inventors: Florence Roger, Fabien Vaudant, Thierry Rimlinger, Christian Ebert, Rodrigue Chatton, Alexander Degen, Kevin Reitz, Torsten Brandenburger
  • Patent number: 11591576
    Abstract: Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: February 28, 2023
    Assignee: Isolere Bio, Inc.
    Inventors: Kelli M. Luginbuhl, Michael Dzuricky
  • Patent number: 11591396
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: February 28, 2023
    Inventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
  • Patent number: 11590223
    Abstract: Administration regimens for therapeutic proteins (e.g., T cell-activating bispecific antibodies) that mitigate cytokine release syndrome and infusion-related reaction are disclosed. The methods employ initial fractional dosing with optional administration of additional agents such as steroids or cytokine antagonists that are discontinued with maximal weekly dosing over the course of the dosing regimen.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: February 28, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Carrie Brownstein, Israel Lowy, Lieve Lucille Adriaens
  • Patent number: 11584794
    Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: February 21, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • Patent number: 11584792
    Abstract: Described herein are methods of treating COVID19 from a coronavirus infection, methods of treating a subject having a coronavirus infection, methods of improving a survival rate of a subject having a coronavirus infection, methods of determining prognosis of a subject having a coronavirus infection, methods of preventing or treating organ-dysfunction or multi-organ dysfunction or failure associated with a coronavirus infection, methods of combinational therapy for a subject having a coronavirus infection, methods of reducing microthrombi formation or low flow organ-ischemia associated with a coronavirus infection by administering a DEspR inhibitor.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: February 21, 2023
    Inventors: Nelson Ruiz-Opazo, Victoria Herrera
  • Patent number: 11584787
    Abstract: Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: February 21, 2023
    Inventors: Alan F. List, Sheng Wei
  • Patent number: 11578136
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 14, 2023
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Patent number: 11571461
    Abstract: The present invention relates to the use of a CD24 protein for treating Systemic Lupus Erythematosus (Lupus, SLE).
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: February 7, 2023
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Pan Zheng, Martin Devenport
  • Patent number: 11548941
    Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: January 10, 2023
    Inventors: Julianty Angsana, Patrick Branigan, Samuel DePrimo, Susan Flavin, Shu Li, Xuejun Liu, Ernesto Munoz, Bruce Randazzo
  • Patent number: 11542312
    Abstract: Human interleukin-2 (IL-2) muteins or variants thereof are provided. In particular, provided are IL-2 muteins that have an increased binding capacity for IL-2R? receptor as compared to wild-type IL-2 for use in combination therapies with anti-PD-1 antibodies for the treatment of cancer. Also provided are pharmaceutical compositions that include such anti-PD-1 antibodies and the disclosed IL-2 muteins.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: January 3, 2023
    Assignee: Medicenna Therapeutics, Inc.
    Inventors: Fahar Merchant, Shafique Fidai